A Study of SYS6051 in Subjects With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorCSPC Megalith Biopharmaceutical Co.,Ltd.
About this trial
This is a multicenter, open-label, dose-escalation and backfill, and cohort-expansion phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor efficacy of SYS6051 in participants with advanced solid tumors.
Eligibility criteria
Qualifiers
Fully understand the clinical study and voluntarily sign the written ICF;
Age ≥ 18 years;
Have at least one measurable lesion according to RECIST 1.1;
ECOG performance status score of 0 to 1;
Disqualifiers
None
Trial design
Treatments tested in this trial
- SYS6051
Treatment groups
114 Participants
are divided into 1 treatment groupLocations
Sponsors and collaborators
Source ClinicalTrials.gov